Your browser doesn't support javascript.
loading
Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer.
Hampras, Shalaka S; Sucheston-Campbell, Lara E; Cannioto, Rikki; Chang-Claude, Jenny; Modugno, Francesmary; Dörk, Thilo; Hillemanns, Peter; Preus, Leah; Knutson, Keith L; Wallace, Paul K; Hong, Chi-Chen; Friel, Grace; Davis, Warren; Nesline, Mary; Pearce, Celeste L; Kelemen, Linda E; Goodman, Marc T; Bandera, Elisa V; Terry, Kathryn L; Schoof, Nils; Eng, Kevin H; Clay, Alyssa; Singh, Prashant K; Joseph, Janine M; Aben, Katja K H; Anton-Culver, Hoda; Antonenkova, Natalia; Baker, Helen; Bean, Yukie; Beckmann, Matthias W; Bisogna, Maria; Bjorge, Line; Bogdanova, Natalia; Brinton, Louise A; Brooks-Wilson, Angela; Bruinsma, Fiona; Butzow, Ralf; Campbell, Ian G; Carty, Karen; Cook, Linda S; Cramer, Daniel W; Cybulski, Cezary; Dansonka-Mieszkowska, Agnieszka; Dennis, Joe; Despierre, Evelyn; Dicks, Ed; Doherty, Jennifer A; du Bois, Andreas; Dürst, Matthias; Easton, Doug.
Afiliação
  • Hampras SS; Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida, USA.
  • Sucheston-Campbell LE; College of Pharmacy, The Ohio State University, Columbus, Ohio, USA.
  • Cannioto R; Department of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, Ohio, USA.
  • Chang-Claude J; Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York, USA.
  • Modugno F; German Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Heidelberg, Germany.
  • Dörk T; Department of Epidemiology and Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Hillemanns P; Women's Cancer Research Program, Magee-Women's Research Institute and University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA.
  • Preus L; Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.
  • Knutson KL; Clinics of Obstetrics and Gynaecology, Hannover Medical School, Hannover, Germany.
  • Wallace PK; Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York, USA.
  • Hong CC; Department of Immunology, Mayo Clinic, Rochester, Minnesota, USA.
  • Friel G; Department of Flow & Image Cytometry, Roswell Park Cancer Institute, Buffalo, New York, USA.
  • Davis W; Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York, USA.
  • Nesline M; Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York, USA.
  • Pearce CL; Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York, USA.
  • Kelemen LE; Center for Personalized Medicine, Roswell Park Cancer Institute, Buffalo, New York, USA.
  • Goodman MT; Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, USA.
  • Bandera EV; Alberta Health Services-Cancer Care, Department of Population Health Research, Calgary, Alberta, Canada.
  • Terry KL; Cancer Prevention and Control, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Schoof N; Cancer Prevention and Control, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.
  • Eng KH; Obstetrics and Gynecology Center, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Clay A; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Singh PK; Department of Biostatistics & Bioinformatics, Roswell Park Cancer Institute, Buffalo, New York, USA.
  • Joseph JM; Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York, USA.
  • Aben KK; Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York, USA.
  • Anton-Culver H; Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York, USA.
  • Antonenkova N; Department for Health Evidence, Radboud University Medical Centre, Nijmegen, The Netherlands.
  • Baker H; Department of Epidemiology and School of Medicine, University of California Irvine, Irvine, California, USA.
  • Bean Y; Byelorussian Institute for Oncology and Medical Radiology Aleksandrov N.N., Minsk, Belarus.
  • Beckmann MW; Department of Oncology, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK.
  • Bisogna M; Department of Obstetrics & Gynecology and Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.
  • Bjorge L; Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany.
  • Bogdanova N; Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Brinton LA; Department of Gynecology and Obstetrics, Haukeland University Hospital, Bergen, Norway.
  • Brooks-Wilson A; Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.
  • Bruinsma F; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.
  • Butzow R; Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia, Canada.
  • Campbell IG; Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Australia.
  • Carty K; Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.
  • Cook LS; Cancer Genetics Laboratory, Research Division, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Australia.
  • Cramer DW; Cancer Research UK Clinical Trials Unit, The Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow, UK.
  • Cybulski C; Division of Epidemiology and Biostatistics, Department of Internal Medicine, University of New Mexico, Albuquerque, New Mexico, USA.
  • Dansonka-Mieszkowska A; Obstetrics and Gynecology Center, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Dennis J; International Hereditary Cancer Center, Department of Genetics and Pathology, Clinic of Opthalmology, Pomeranian Medical University, Szczecin, Poland.
  • Despierre E; Department of Pathology and Labolatory Diagnostic, The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.
  • Dicks E; Department of Oncology, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK.
  • Doherty JA; Division of Gynecological Oncology, Department of Oncology, University Hospitals Leuven, Belgium.
  • du Bois A; Department of Oncology, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK.
  • Dürst M; Department of Community and Family Medicine, Section of Biostatistics & Epidemiology, The Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA.
  • Easton D; Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/ Knappschaft GmbH, Essen, Germany.
Oncotarget ; 7(43): 69097-69110, 2016 10 25.
Article em En | MEDLINE | ID: mdl-27533245
ABSTRACT

BACKGROUND:

Regulatory T (Treg) cells, a subset of CD4+ T lymphocytes, are mediators of immunosuppression in cancer, and, thus, variants in genes encoding Treg cell immune molecules could be associated with ovarian cancer.

METHODS:

In a population of 15,596 epithelial ovarian cancer (EOC) cases and 23,236 controls, we measured genetic associations of 1,351 SNPs in Treg cell pathway genes with odds of ovarian cancer and tested pathway and gene-level associations, overall and by histotype, for the 25 genes, using the admixture likelihood (AML) method. The most significant single SNP associations were tested for correlation with expression levels in 44 ovarian cancer patients.

RESULTS:

The most significant global associations for all genes in the pathway were seen in endometrioid ( p = 0.082) and clear cell ( p = 0.083), with the most significant gene level association seen with TGFBR2 ( p = 0.001) and clear cell EOC. Gene associations with histotypes at p < 0.05 included IL12 ( p = 0.005 and p = 0.008, serous and high-grade serous, respectively), IL8RA ( p = 0.035, endometrioid and mucinous), LGALS1 ( p = 0.03, mucinous), STAT5B ( p = 0.022, clear cell), TGFBR1 ( p = 0.021 endometrioid) and TGFBR2 ( p = 0.017 and p = 0.025, endometrioid and mucinous, respectively).

CONCLUSIONS:

Common inherited gene variation in Treg cell pathways shows some evidence of germline genetic contribution to odds of EOC that varies by histologic subtype and may be associated with mRNA expression of immune-complex receptor in EOC patients.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Proteínas Serina-Treonina Quinases / Receptores de Fatores de Crescimento Transformadores beta / Adenocarcinoma de Células Claras / Neoplasias Epiteliais e Glandulares / Predisposição Genética para Doença / Polimorfismo de Nucleotídeo Único Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Proteínas Serina-Treonina Quinases / Receptores de Fatores de Crescimento Transformadores beta / Adenocarcinoma de Células Claras / Neoplasias Epiteliais e Glandulares / Predisposição Genética para Doença / Polimorfismo de Nucleotídeo Único Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article